<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138470">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298440</url>
  </required_header>
  <id_info>
    <org_study_id>AvastinRFI</org_study_id>
    <nct_id>NCT01298440</nct_id>
  </id_info>
  <brief_title>Bevacizumab Effect on Blood Velocity</brief_title>
  <official_title>The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optical Imaging, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optical Imaging, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is
      correlated to treatment success.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study was to carry out a pilot study on the short-term effect of
      intravitreal Bevacizumab (Avastin) injection on retinal blood-flow velocity and test whether
      the short-term haemodynamic changes could predict the longer term clinical result of the
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood flow velocity change</measure>
    <time_frame>1 day following injection</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">12</enrollment>
  <condition>Choroidal Neovascularization</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with choroidal neovascularization (CNV)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CNV receiving Bevacizumab intravitreal injection

        Exclusion Criteria:

          -  Candidates in whom the retina could not be seen clearly because of media opacity or a
             poorly dilating pupil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adiel Barak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel aviv university Sackler school of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tel aviv sourasky medical center</name>
      <address>
        <city>Tel aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <lastchanged_date>February 16, 2011</lastchanged_date>
  <firstreceived_date>February 16, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Optical Imaging, Ltd</name_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
